Publication

Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis

Ankrah, A. O., Lawal, I. O., Boshomane, T. M. G., Klein, H. C., Ebenhan, T., Dierckx, R. A. J. O., Vorster, M., Glaudemans, A. W. J. M. & Sathekge, M. M., Sep-2019, In : Nuklearmedizin-Nuclear medicine. 58, 5, p. 371-378 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Ankrah, A. O., Lawal, I. O., Boshomane, T. M. G., Klein, H. C., Ebenhan, T., Dierckx, R. A. J. O., Vorster, M., Glaudemans, A. W. J. M., & Sathekge, M. M. (2019). Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis. Nuklearmedizin-Nuclear medicine, 58(5), 371-378. https://doi.org/10.1055/a-1000-6951

Author

Ankrah, Alfred O. ; Lawal, Ismaheel O. ; Boshomane, Tebatso M. G. ; Klein, Hans C. ; Ebenhan, Thomas ; Dierckx, Rudi A. J. O. ; Vorster, Mariza ; Glaudemans, Andor W. J. M. ; Sathekge, Mike M. / Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis. In: Nuklearmedizin-Nuclear medicine. 2019 ; Vol. 58, No. 5. pp. 371-378.

Harvard

Ankrah, AO, Lawal, IO, Boshomane, TMG, Klein, HC, Ebenhan, T, Dierckx, RAJO, Vorster, M, Glaudemans, AWJM & Sathekge, MM 2019, 'Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis', Nuklearmedizin-Nuclear medicine, vol. 58, no. 5, pp. 371-378. https://doi.org/10.1055/a-1000-6951

Standard

Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis. / Ankrah, Alfred O.; Lawal, Ismaheel O.; Boshomane, Tebatso M. G.; Klein, Hans C.; Ebenhan, Thomas; Dierckx, Rudi A. J. O.; Vorster, Mariza; Glaudemans, Andor W. J. M.; Sathekge, Mike M.

In: Nuklearmedizin-Nuclear medicine, Vol. 58, No. 5, 09.2019, p. 371-378.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Ankrah AO, Lawal IO, Boshomane TMG, Klein HC, Ebenhan T, Dierckx RAJO et al. Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis. Nuklearmedizin-Nuclear medicine. 2019 Sep;58(5):371-378. https://doi.org/10.1055/a-1000-6951


BibTeX

@article{c56a08b2edf14465bc89b0708ea135aa,
title = "Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis",
abstract = "(18) F-FDG and (68) Ga-citrate PET/CT have both been shown to be useful in the management of tuberculosis (TB). We compared the abnormal PET findings of (18) F-FDG- and (68) Ga-citrate-PET/CT in patients with TB. Methods Patients with TB on anti-TB therapy were included. Patients had a set of PET scans consisting of both (18) F-FDG and (68) Ga-citrate. Abnormal lesions were identified, and the two sets of scans were compared. The scan findings were correlated to the clinical data as provided by the attending physician. Results 46 PET/CT scans were performed in 18 patients, 11 (61 %) were female, and the mean age was 35.7 +/- 13.5 years. Five patients also had both studies for follow-up reasons during the use of anti-TB therapy. Thirteen patients were co-infected with HIV. (18) F-FDG detected more lesions than (68) Ga-citrate (261 vs. 166, p <0.0001). (68) Ga-citrate showed a better definition of intracerebral lesions due to the absence of tracer uptake in the brain. The mean SUVmax was higher for (18) F-FDG compared to (68) Ga-citrate (5.73 vs. 3.01, p <0.0001). We found a significant correlation between the SUVmax of lesions that were determined by both tracers (r = 0.4968, p <0.0001). Conclusion Preliminary data shows (18) F-FDG-PET detects more abnormal lesions in TB compared to (68) Ga-citrate. However, (68) Ga-citrate has better lesion definition in the brain and is therefore especially useful when intracranial TB is suspected.",
keywords = "Tuberculosis, (18) F-FDG, (68) Ga-citrate, PET, CT, NEGATIVE PULMONARY TUBERCULOSIS, GA-68-CITRATE PET/CT, INFECTION, DIAGNOSIS, GENERATOR, ALGORITHM",
author = "Ankrah, {Alfred O.} and Lawal, {Ismaheel O.} and Boshomane, {Tebatso M. G.} and Klein, {Hans C.} and Thomas Ebenhan and Dierckx, {Rudi A. J. O.} and Mariza Vorster and Glaudemans, {Andor W. J. M.} and Sathekge, {Mike M.}",
year = "2019",
month = sep,
doi = "10.1055/a-1000-6951",
language = "English",
volume = "58",
pages = "371--378",
journal = "Nuclear medicine-Nuklearmedizin",
issn = "0029-5566",
publisher = "GEORG THIEME VERLAG KG",
number = "5",

}

RIS

TY - JOUR

T1 - Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis

AU - Ankrah, Alfred O.

AU - Lawal, Ismaheel O.

AU - Boshomane, Tebatso M. G.

AU - Klein, Hans C.

AU - Ebenhan, Thomas

AU - Dierckx, Rudi A. J. O.

AU - Vorster, Mariza

AU - Glaudemans, Andor W. J. M.

AU - Sathekge, Mike M.

PY - 2019/9

Y1 - 2019/9

N2 - (18) F-FDG and (68) Ga-citrate PET/CT have both been shown to be useful in the management of tuberculosis (TB). We compared the abnormal PET findings of (18) F-FDG- and (68) Ga-citrate-PET/CT in patients with TB. Methods Patients with TB on anti-TB therapy were included. Patients had a set of PET scans consisting of both (18) F-FDG and (68) Ga-citrate. Abnormal lesions were identified, and the two sets of scans were compared. The scan findings were correlated to the clinical data as provided by the attending physician. Results 46 PET/CT scans were performed in 18 patients, 11 (61 %) were female, and the mean age was 35.7 +/- 13.5 years. Five patients also had both studies for follow-up reasons during the use of anti-TB therapy. Thirteen patients were co-infected with HIV. (18) F-FDG detected more lesions than (68) Ga-citrate (261 vs. 166, p <0.0001). (68) Ga-citrate showed a better definition of intracerebral lesions due to the absence of tracer uptake in the brain. The mean SUVmax was higher for (18) F-FDG compared to (68) Ga-citrate (5.73 vs. 3.01, p <0.0001). We found a significant correlation between the SUVmax of lesions that were determined by both tracers (r = 0.4968, p <0.0001). Conclusion Preliminary data shows (18) F-FDG-PET detects more abnormal lesions in TB compared to (68) Ga-citrate. However, (68) Ga-citrate has better lesion definition in the brain and is therefore especially useful when intracranial TB is suspected.

AB - (18) F-FDG and (68) Ga-citrate PET/CT have both been shown to be useful in the management of tuberculosis (TB). We compared the abnormal PET findings of (18) F-FDG- and (68) Ga-citrate-PET/CT in patients with TB. Methods Patients with TB on anti-TB therapy were included. Patients had a set of PET scans consisting of both (18) F-FDG and (68) Ga-citrate. Abnormal lesions were identified, and the two sets of scans were compared. The scan findings were correlated to the clinical data as provided by the attending physician. Results 46 PET/CT scans were performed in 18 patients, 11 (61 %) were female, and the mean age was 35.7 +/- 13.5 years. Five patients also had both studies for follow-up reasons during the use of anti-TB therapy. Thirteen patients were co-infected with HIV. (18) F-FDG detected more lesions than (68) Ga-citrate (261 vs. 166, p <0.0001). (68) Ga-citrate showed a better definition of intracerebral lesions due to the absence of tracer uptake in the brain. The mean SUVmax was higher for (18) F-FDG compared to (68) Ga-citrate (5.73 vs. 3.01, p <0.0001). We found a significant correlation between the SUVmax of lesions that were determined by both tracers (r = 0.4968, p <0.0001). Conclusion Preliminary data shows (18) F-FDG-PET detects more abnormal lesions in TB compared to (68) Ga-citrate. However, (68) Ga-citrate has better lesion definition in the brain and is therefore especially useful when intracranial TB is suspected.

KW - Tuberculosis

KW - (18) F-FDG

KW - (68) Ga-citrate

KW - PET

KW - CT

KW - NEGATIVE PULMONARY TUBERCULOSIS

KW - GA-68-CITRATE PET/CT

KW - INFECTION

KW - DIAGNOSIS

KW - GENERATOR

KW - ALGORITHM

U2 - 10.1055/a-1000-6951

DO - 10.1055/a-1000-6951

M3 - Article

VL - 58

SP - 371

EP - 378

JO - Nuclear medicine-Nuklearmedizin

JF - Nuclear medicine-Nuklearmedizin

SN - 0029-5566

IS - 5

ER -

ID: 98546527